What we gained from a century of investigations of symbiontic intestinal microflora


Cite item

Full Text

Abstract

Symbiontic microflora prevents contamination of human intestine with foreign microflora; microbial enzymes split cellular tissue, proteins, fat, starch, deconjugate bile acids, synthetize B vitamins, amino acids, cholesterol and other substances. Microbial metabolism products - short-chain fatty acids - stimulate intestinal motility and are effective in some intestinal diseases. Bacterial therapy is able to modulate immune system and suppress chemical signalization of pathogenic microbes. Probiotics and functional nutrition represent a perspective trend in prophylaxis and treatment of human diseases. A criterion of probiotic efficacy is its ability to suppress foreign microflora and maintenance of normal microbial flora of the host. An essential probiotic function - support of normal immune system. In the future, probiotics will be employed in prevention and treatment of many human diseases. New probiotics and other forms of biopreparations should be designed basing on various species of symbiontic intestinal microflora.

About the authors

Asfol'd Ivanovich Parfenov

Email: asfold@mail.ru

Viktor Mikhaylovich Bondarenko

Email: bvm@gamaleya.org

A I Parfenov

Central Research Institute of Gastroenterology, Moscow

Central Research Institute of Gastroenterology, Moscow

V M Bondarenko

N.F. Gamalei Research Institute for Epidemiology and Microbiology, Moscow

N.F. Gamalei Research Institute for Epidemiology and Microbiology, Moscow

References

  1. Dethlefsen L., McFall-Ngai M., Relman D. A. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 2007; 449: 811-818.
  2. Gill S. R., Pop M., Deboy R. T. et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-1359.
  3. Бондаренко В. М., Мацулевич Т. В. Дисбактериоз кишечника как клинико-лабораторный синдром: современное состояние проблемы. М.: ГЭОТАР-медиа; 2007.
  4. Eckburg P. B., Bik E. M., Bernstein C. N. et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638.
  5. Madara J. L., Nash S., Moore R. et al. Structure and function of the intestinal epithelial barrier in health and disease. Monogr. Pathol. 1990; 31: 306-324.
  6. Уголев А. М., Иезуитова Н. Н., Тимофеева Н. М. Энзиматический барьер тонкой кишки. Физиол. журн. им. И. М. Сеченова. 1992; 78 (8): 1-20.
  7. Laukoetter M. G., Nava P., Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. Wld J. Gastroenterol. 2008; 14: 401-407.
  8. Бондаренко В. М., Рябиченко Е. В. Роль дисфункции кишечного барьера в поддержании хронического воспалительного процесса различной локализации. Журн. микробиол. 2010; 1: 92-100.
  9. Madsen K., Cornish A., Soper P. et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591.
  10. Pull S. L., Doherty J. M., Mills J. C. et al. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc. Natl. Acad. Sci. USA 2005; 102: 99-104.
  11. Бондаренко В. М., Лиходед В. Г. Взаимодействие кишечной микрофлоры с Toll-подобными рецепторами в норме и патологии. Иммунология 2009; 5: 317-320.
  12. Ayabe T., Satchell D. P., Wilson C. L. et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol. 2000; 1: 113-118.
  13. Melmed G., Thomas L. S., Lee N. et al. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J. Immunol. 2003; 170: 1406-1415.
  14. Kelly D., Conway S., Aminov R. Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol. 2005; 26: 326-333.
  15. Yan F., Cao H., Cover T. L. et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007; 132: 562-575.
  16. Neutra M. R., Mantis N. J., Kraehenbuhl J. P. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat. Immunol. 2001; 2: 1004-1009.
  17. Mazmanian S. K., Round J. L., Kasper D. L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008; 453: 620-625.
  18. Cooper M. D., Alder M. N. The evolution of adaptive immune systems. Cell 2006; 124: 815-822.
  19. McFall-Ngai M. Adaptive immunity: care for the community. Nature 2007; 445: 153.
  20. Macpherson A. J., Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004; 303: 1662-1665.
  21. Mazmanian S. K., Liu C. H., Tzianabos A. O. et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122: 107-118.
  22. Zaph C., Du Y., Saenz S. A. et al. Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J. Exp. Med. 2008; 205: 2191-2198.
  23. Bergman E. Energy contribution of volitile fatty acids from the gastrointestinal tract in various species. Physiol. Rev. 1990; 70: 567-590.
  24. Ардатская М. Д., Минушкин О. Н. Дисбактериозы кишечника: эволюция взглядов, современные принципы диагностики и фармакологической коррекции. Consilium Medicum. Гастроэнтерология 2006; 2: 4-17.
  25. Бондаренко В. М. Метаболитные пробиотики: механизмы терапевтического эффекта при микроэкологических нарушениях. Consilium Medicum. Гастроэнтерология 2005; 7: 437-443.
  26. Turnbaugh P. J., Ley R. E., Mahowald M. A. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031.
  27. Vernia P., Annese V., Bresci G. et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur. J. Clin. Invest. 2003; 33: 244-248.
  28. Vijay-Kumar M., Aitken J. D., Sanders C. J. et al. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J. Immunol. 2008; 180: 8280-8285.
  29. Ley R. E., Turnbaugh P. J., Klein S. et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023.
  30. Tennyson C. A., Friedman G. Microecology, obesity and probiotics. Curr. Opin. Endocrinol. Diabet. Obes. 2008; 15 (5): 422-.427.
  31. Лазебник Л. Б. Гепатоцит и атеросклероз. Клин. геронтология 2012; 1:3-8.
  32. Бондаренко В. М., Лиходед В. Г., Микробный фактор и Тоll-подобные рецепторы в патогенезе атеросклероза. Журн. микробиол. 2009; 6: 107-112.
  33. Strachan D. P. Hay fever, hygiene, and household size. Br. Med. J. 1989; 299: 1259-1260.
  34. Bach J.-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 2002; 347: 911-920.
  35. von Mutius E. Allergies, infections and the hygiene hypothesis-the epidemiological evidence. Immunobiology 2007; 212: 433-439.
  36. Boirivant M., Strober W. The mechanism of action of probiotics. Curr. Opin. Gastroenterol. 2007; 23: 679-692.
  37. Sartor R. B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-594.
  38. Garrett W. S., Lord G. M., Punit S. et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007; 131: 33-45.
  39. Vollaard E. J., Clasener H. A. Colonization resistance. Antimicrob. Agents Chemother. 1994; 38: 409-414.
  40. Kaper J. B., Sperandio V. Bacterial cell-to-cell signaling in the gastrointestinal tract. Infect. and Immun. 2005; 73: 3197-3209.
  41. Петров Л. Н., Бондаренко В. М., Вахитов Т. Я. QS-системы у бактерий и перспективы создания новых метаболитных пробиотических препаратов. Вестн. РАМН 2006, 1: 38-45.
  42. Парфенов А. И. Энтерология. 2-е изд. М.: МИА; 2009.
  43. Park J., Floch M. H. Prebiotics, probiotics, and dietary fiber in gastrointestinal disease. Gastroenterol. Clin. N. Am. 2007; 36: 47-63.
  44. Hamer H. M., Jonkers D., Venema K. et al. Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther. 2008; 27: 104-119.
  45. Besselink M. G., van Santvoort H. C., Buskens E. et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-659.
  46. Бондаренко В. М. Характеристика и терапевтический потенциал пробиотиков по данным клинических испытаний. БиоПрепараты 2007; 1: 11-15.
  47. Бондаренко В. М. Пребиотическое и противоинфекционное действие лактулозосодержащих препаратов. Фарматека 2004; 11: 25-30.
  48. Lebeer S., Vanderleyden J., de Keersmaecker S. C. Genes and molecules of lactobacilli supporting probiotic action. Microbiol. Mol. Biol. Rev. 2008; 72 (4): 728-764.
  49. Бондаренко В. М. Молекулярно-клеточные механизмы терапевтического действия пробиотиков. БиоПрепараты 2010; 1: 31-34.
  50. Walter J. Ecological role of Lactobacilli in the gastrointestinal tract: implication for fundamental and biomedical research. Appl. Envir. Microbiol. 2008; 74 (16): 4985-4996.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies